{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T16:01:18Z","timestamp":1779379278002,"version":"3.53.1"},"reference-count":77,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.beha.2025.101649","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T20:21:51Z","timestamp":1754425311000},"page":"101649","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Bispecific T-cell engager therapy for multiple myeloma"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5719-581X","authenticated-orcid":false,"given":"Diana","family":"Cirstea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Puliafito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget E.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noopur","family":"Raje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2025.101649_bib1","doi-asserted-by":"crossref","DOI":"10.1111\/ejh.13083","article-title":"Rapidly changing myeloma epidemiology in the general population: increased incidence, older patients, and longer survival","author":"Turesson","year":"2018","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.beha.2025.101649_bib2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/JOP.19.00244","article-title":"Current treatment strategies for multiple myeloma","volume":"16","author":"Branagan","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.beha.2025.101649_bib3","first-page":"1","article-title":"Newly diagnosed Myeloma in 2020","volume":"40","author":"Moreau","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"9","key":"10.1016\/j.beha.2025.101649_bib4","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.beha.2025.101649_bib5","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"10297","key":"10.1016\/j.beha.2025.101649_bib6","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.beha.2025.101649_bib7","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2025.101649_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"24","key":"10.1016\/j.beha.2025.101649_bib9","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell\u2013Redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.beha.2025.101649_bib10","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1182\/hematology.2023000433","article-title":"Current use of bispecific antibodies to treat multiple myeloma","volume":"2023","author":"Lee","year":"2023","journal-title":"Hematology"},{"key":"10.1016\/j.beha.2025.101649_bib11","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B Cell Maturation Antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front Immunol"},{"issue":"25","key":"10.1016\/j.beha.2025.101649_bib12","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101649_bib13","series-title":"Clinical lymphoma myeloma and leukemia","article-title":"Comprehensive review of bispecific antibody constructs in multiple myeloma: affinities, dosing strategies and future perspectives","author":"Waldschmidt","year":"2024"},{"issue":"5","key":"10.1016\/j.beha.2025.101649_bib14","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1158\/2643-3230.BCD-21-0028","article-title":"Bispecific antibodies in multiple myeloma: present and future","volume":"2","author":"Lancman","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"10.1016\/j.beha.2025.101649_bib15","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41408-024-01139-y","article-title":"Bispecific antibodies in the treatment of multiple myeloma","volume":"14","author":"Devasia","year":"2024","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.beha.2025.101649_bib16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1053\/j.seminoncol.2022.01.004","article-title":"Harnessing natural killer cells for the treatment of multiple myeloma","volume":"49","author":"Clara","year":"2022","journal-title":"Semin Oncol"},{"key":"10.1016\/j.beha.2025.101649_bib17","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1182\/blood-2023-182130","article-title":"Long-term efficacy and safety of elranatamab monotherapy in the phase 2 Magnetismm-3 trial in relapsed or refractory multiple myeloma (RRMM)","volume":"142","author":"Tomasson","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101649_bib18","series-title":"Patients with relapsed\/refractory multiple myeloma. European Hematology association 2024 hybrid congress; Jun 13\u201316, 2024; Madrid, ES","article-title":"Long-term efficacy and safety results from the phase 1\/2 MonumenTAL-1 study of talquetamab, a GPRC5D\u00d7CD3 bispecific antibody","author":"Leo","year":"2024"},{"issue":"508","key":"10.1016\/j.beha.2025.101649_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax8861","article-title":"CD3 bispecific antibody\u2013induced cytokine release is dispensable for cytotoxic T cell activity","volume":"11","author":"Li","year":"2019","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.beha.2025.101649_bib20","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.beha.2025.101649_bib21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/17474086.2019.1585238","article-title":"Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy","volume":"12","author":"Acharya","year":"2019","journal-title":"Expet Rev Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101649_bib22","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1182\/blood-2024-203426","article-title":"Tocilizumab prophylaxis for patients with relapsed or refractory multiple myeloma treated with teclistamab, Elranatamab or talquetamab","volume":"144","author":"Kowalski","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101649_bib23","series-title":"ASCO annual meeting; Chicago, IL","article-title":"Implementing the bispecific outpatient safe step-up (BOSS) program for elranatamab in ambulatory treatment of multiple myeloma","author":"Diana","year":"2025"},{"issue":"6","key":"10.1016\/j.beha.2025.101649_bib24","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cncr.35107","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC\u20101 study","volume":"130","author":"Nooka","year":"2024","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.beha.2025.101649_bib25","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41375-021-01506-9","article-title":"Inflammation and infection in plasma cell disorders: how pathogens shape the fate of patients","volume":"36","author":"Caro","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.beha.2025.101649_bib26","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41408-024-01091-x","article-title":"Improving outcomes with anti-BCMA bispecific antibodies with attention to infection","volume":"14","author":"Yee","year":"2024","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.beha.2025.101649_bib27","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.beha.2025.101649_bib28","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with Anti-BCMA bispecific antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"10.1016\/j.beha.2025.101649_bib29","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-025-01282-0","article-title":"Effect of Intravenous Immunoglobulin (IVIG) supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma","volume":"15","author":"Mohan","year":"2025","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.beha.2025.101649_bib30","series-title":"Durability of responses with biweekly dosing of teclistamab in patients with relapsed\/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study","author":"Usmani","year":"2023"},{"key":"10.1016\/j.beha.2025.101649_bib31","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1182\/blood-2023-177735","article-title":"A phase 2, single-arm, non-inferiority study of limited-duration teclistamab for relapsed and refractory multiple myeloma (LimiTec)","volume":"142","author":"Razzo","year":"2023","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2025.101649_bib32","first-page":"1104","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals. Blood","volume":"140","author":"Philipp","year":"2022","journal-title":"J Am Soc Hematol"},{"key":"10.1016\/j.beha.2025.101649_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00962-7","article-title":"BCMA-targeted immunotherapy for multiple myeloma","volume":"13","author":"Yu","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"8","key":"10.1016\/j.beha.2025.101649_bib34","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"485","key":"10.1016\/j.beha.2025.101649_bib35","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101649_bib36","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood-2024-199542","volume":"144","author":"Richter","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101649_bib37","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1182\/blood-2024-210518","article-title":"Long-term Follow-up of real-world teclistamab therapy for relapsed\/refractory multiple myeloma from the IMWG immunotherapy working group committee","volume":"144","author":"Tan","year":"2024","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.beha.2025.101649_bib38","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.2217\/fon-2023-0995","article-title":"Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma","volume":"20","author":"Costa","year":"2024","journal-title":"Future Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101649_bib39","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1182\/blood-2024-211167","article-title":"Real world evidence of outcomes of patients treated with talquetamab in a heavily pretreated population with multiple myeloma with high exposure to prior BCMA Therapies- a report from the IMWG consortium","volume":"144","author":"Janakiram","year":"2024","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.beha.2025.101649_bib40","doi-asserted-by":"crossref","first-page":"8011","DOI":"10.1200\/JCO.2023.41.16_suppl.8011","article-title":"Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Moreau","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.beha.2025.101649_bib41","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1182\/bloodadvances.2023012354","article-title":"Mechanisms of resistance to bispecific T-cell engagers in multiple myeloma and their clinical implications","volume":"8","author":"Letouz\u00e9","year":"2024","journal-title":"Blood Adv"},{"issue":"19","key":"10.1016\/j.beha.2025.101649_bib42","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/bloodadvances.2021004418","article-title":"Single-and double-hit events in genes encoding immune targets before and after T cell\u2013engaging antibody therapy in MM","volume":"5","author":"Truger","year":"2021","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.beha.2025.101649_bib43","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA-or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.beha.2025.101649_bib44","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s43018-023-00625-9","article-title":"Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation","volume":"4","author":"Derrien","year":"2023","journal-title":"Nat Cancer"},{"issue":"4","key":"10.1016\/j.beha.2025.101649_bib45","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.beha.2025.101649_bib46","first-page":"3078","article-title":"Clonal CD8(+) T-cell expansion is associated with complete response to elranatamab in refractory multiple myeloma","volume":"109","author":"Krzysiek","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2025.101649_bib47","series-title":"First results from the RedirecTT-1 study with teclistamab (tec)+ talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","author":"Cohen","year":"2023"},{"issue":"4","key":"10.1016\/j.beha.2025.101649_bib48","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/2643-3230.BCD-21-0038","article-title":"Tumor burden limits bispecific antibody efficacy through T-cell exhaustion averted by concurrent cytotoxic therapy","volume":"2","author":"Meermeier","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"S2","key":"10.1016\/j.beha.2025.101649_bib49","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/01.HS9.0000936256.84340.a7","article-title":"P32 Majestec-1: correlative analyses of teclistamab, a B-cell maturation antigen (BCMA) X CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"7","author":"van de Donk","year":"2023","journal-title":"Hemasphere"},{"issue":"17","key":"10.1016\/j.beha.2025.101649_bib50","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1182\/bloodadvances.2020002524","article-title":"The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models","volume":"4","author":"Cho","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.beha.2025.101649_bib51","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1158\/1078-0432.CCR-19-2299","article-title":"Preclinical activity of JNJ-7957, a novel BCMA\u00d7CD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by daratumumab","volume":"26","author":"Frerichs","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.beha.2025.101649_bib52","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Adv"},{"issue":"S3","key":"10.1016\/j.beha.2025.101649_bib53","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000970364.16259.0e","article-title":"P865: teclistamab in combination with lenalidomide in previously treated patients with multiple myeloma in the phase 1B multicohort MAJESTEC-2 study","volume":"7","author":"Tan","year":"2023","journal-title":"HemaSphere"},{"issue":"16_suppl","key":"10.1016\/j.beha.2025.101649_bib54","doi-asserted-by":"crossref","first-page":"8032","DOI":"10.1200\/JCO.2022.40.16_suppl.8032","article-title":"A novel, immunotherapy-based approach for the treatment of relapsed\/refractory multiple myeloma (RRMM): updated phase 1b results for daratumumab in combination with teclistamab (a BCMA x CD3 bispecific antibody)","volume":"40","author":"Rodr\u00edguez-Otero","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101649_bib55","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1182\/blood-2022-159711","article-title":"Teclistamab in combination with subcutaneous daratumumab and lenalidomide in patients with multiple myeloma: results from one cohort of MajesTEC-2, a Phase1b, multicohort study","volume":"140","author":"Searle","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101649_bib56","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2024-205083","article-title":"ABBV-383 plus daratumumab-dexamethasone in relapsed or refractory multiple myeloma: a phase 1b dose-escalation and safety expansion study","volume":"144","author":"Rodriguez","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101649_bib57","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1182\/blood-2024-210520","article-title":"Efficacy of Elranatamab (ELRA) in combination with Carfilzomib (CFZ) and dexamethasone (DEX) in the phase 1b MagnetisMM-20 trial in relapsed or refractory multiple myeloma (RRMM)","volume":"144","author":"Tomasson","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101649_bib58","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood-2023-187706","article-title":"Talquetamab + pomalidomide in patients with Relapsed\/refractory multiple myeloma: safety and preliminary efficacy results from the phase 1b MonumenTAL-2 study","volume":"142","author":"Matous","year":"2023","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.beha.2025.101649_bib59","doi-asserted-by":"crossref","first-page":"8003","DOI":"10.1200\/JCO.2023.41.16_suppl.8003","article-title":"Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated TRIMM-2 results","volume":"41","author":"Dholaria","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2025.101649_bib60","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S2152-2650(24)01842-1","article-title":"OA-01 Talquetamab (tal) + Daratumumab (dara) + Pomalidomide (pom) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): results from the phase 1b TRIMM-2 study","volume":"24","author":"Bahlis","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.beha.2025.101649_bib61","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2406536","article-title":"Talquetamab plus Teclistamab in relapsed or refractory multiple myeloma","volume":"392","author":"Cohen","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2025.101649_bib62","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood-2023-182330","article-title":"Clinical outcomes of subsequent therapies in patients with relapsed\/refractory multiple myeloma following talquetamab treatment: analyses from the phase 1\/2 monumenTAL-1 study","volume":"142","author":"Sanchez","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101649_bib63","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000967676.59550.94","article-title":"S191: pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DXCD3 bispecific antibody (BsAb), for relapsed\/refractory multiple myeloma (RRMM)","volume":"7","author":"Touzeau","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.beha.2025.101649_bib64","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1182\/blood-2023-190517","article-title":"Immune and genome profiling of myeloma patients treated with sequential immunotherapies reveal differential non-overlapping mechanisms of resistance","volume":"142","author":"Lee","year":"2023","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.beha.2025.101649_bib65","doi-asserted-by":"crossref","first-page":"7520","DOI":"10.1200\/JCO.2024.42.16_suppl.7520","article-title":"Real world outcome of patients with multiple myeloma who received bispecific antibodies after CAR-T therapy","volume":"42","author":"Bansal","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2025.101649_bib66","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1182\/blood-2024-202017","article-title":"Talquetamab bridging: paving the way to B-Cell maturation antigen (BCMA) CAR-T cell therapy in Relapsed\/refractory multiple myeloma (RRMM)","volume":"144","author":"Dhakal","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101649_bib67","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1182\/blood-2023-187409","article-title":"Sequential T-cell engagement for myeloma (\u201cSTEM\u201d) trial: a phase 2 study of cevostamab consolidation following BCMA CAR T cell therapy","volume":"142","author":"Cohen","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101649_bib68","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1182\/blood-2024-206003","article-title":"Phase 2 study of teclistamab-based induction regimens in patients with transplant-eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): results from the GMMG-HD10\/DSMM-XX (MajesTEC-5) trial","volume":"144","author":"Raab","year":"2024","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.beha.2025.101649_bib69","doi-asserted-by":"crossref","first-page":"7506","DOI":"10.1200\/JCO.2024.42.16_suppl.7506","article-title":"Safety results from the phase 3 MajesTEC-7 study in patients (pts) with transplant ineligible\/not intended newly diagnosed multiple myeloma (NDMM)","volume":"42","author":"Touzeau","year":"2024","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101649_bib70","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1182\/blood-2024-199773","article-title":"Talquetamab, a GPRC5D\u00d7CD3 bispecific antibody, in combination with daratumumab and lenalidomide in patients with newly diagnosed multiple myeloma: safety and efficacy results from the phase 1b Monumental-2 study","volume":"144","author":"Nooka","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101649_bib71","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2024-205608","article-title":"Phase 3 Study of Teclistamab (Tec) in combination with lenalidomide (Len) and Tec alone versus Len alone in Newly Diagnosed Multiple Myeloma (NDMM) as maintenance therapy following autologous stem cell transplantation (ASCT): safety Run-in (SRI) results f","volume":"144","author":"Zamagni","year":"2024","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.beha.2025.101649_bib72","doi-asserted-by":"crossref","first-page":"TPS8066","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8066","article-title":"MagnetisMM-7: an open-label, multicenter, randomized phase 3 study of elranatamab versus lenalidomide in post-transplant patients with newly diagnosed multiple myeloma","volume":"41","author":"Mateos","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2025.101649_bib73","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41408-023-00963-y","article-title":"Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: a single-center experience","volume":"13","author":"Scott","year":"2023","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.beha.2025.101649_bib74","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.132","article-title":"Prophylactic tocilizumab reduces the incidence of cytokine release syndrome in relapsed\/refractory myeloma patients treated with teclistamab: implications for outpatient step-up dosing","volume":"8","author":"Korst","year":"2024","journal-title":"HemaSphere"},{"issue":"16_suppl","key":"10.1016\/j.beha.2025.101649_bib75","doi-asserted-by":"crossref","first-page":"8034","DOI":"10.1200\/JCO.2023.41.16_suppl.8034","article-title":"Durability of responses with biweekly dosing of teclistamab in patients with relapsed\/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study","volume":"41","author":"Usmani","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101649_bib76","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1182\/blood-2023-181228","article-title":"Efficacy and safety of less frequent\/lower intensity dosing of talquetamab in patients with relapsed\/refractory multiple myeloma: results from the phase 1\/2 MonumenTAL-1 study","volume":"142","author":"Chari","year":"2023","journal-title":"Blood"},{"issue":"S3","key":"10.1016\/j.beha.2025.101649_bib77","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000967688.12579.64","article-title":"S194: teclistamab (tec) + nirogacestat (niro) in relapsed\/refractory multiple myeloma (rrmm): the phase 1B MAJESTEC-2 study","volume":"7","author":"Offner","year":"2023","journal-title":"HemaSphere"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692625000556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692625000556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T17:54:44Z","timestamp":1757094884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692625000556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":77,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1521692625000556"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2025.101649","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bispecific T-cell engager therapy for multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2025.101649","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101649"}}